Bli medlem
Bli medlem

Du är här


Sanofi : Sanofi and the Iran Ministry of Health and Medical Education Sign a Memorandum of Cooperation

Sanofi and the Iran Ministry of Health and Medical Education Sign a Memorandum
of Cooperation

- Several projects will be studied to further develop existing local
manufacturing collaborations and work on programs to fight chronic and
non-communicable diseases -

Paris and Teheran - January 28, 2016 -
Sanofiand theIran Food and Drug Administration, affiliated to the Ministry of
Health and Medical Education of the Islamic Republic of Iran, have signed a
Memorandum of Cooperation (MoC) to start discussions in order to explore the
possibilities in which Sanofi may lend its know-how and expertise to benefit
the citizens of the Islamic Republic of Iran.

"Sanofi has built a long term presence in Iran and, as the n°1 multinational
healthcare company in this country, is committed to delivering both
innovative and well established healthcare solutions to citizens of Iran,"
said Serge Weinberg, Chairman of the Board of Directors, Sanofi."
With this cooperation, we will consider the possibility to increase our
footprint in Iran, where we have been operating for more than 10 years, and
reinforce our ongoing industrial collaborations

The Memorandum addresses three areas of discussion and potential

Sanofi will study ways in which it could potentially further develop its
current partnerships with reputable Iranian manufacturers to enhance the
sharing of its expertise in industrial quality standards and to increase the
transfer of its pharmaceutical production technology and know-how to
manufacture high quality pharmaceutical products in several fields of chronic
and non-communicable diseases to reputable and reliable Iranian

Sanofi will collaborate with the Ministry of Health on programs for the
prevention and control of certain chronic and non-communicable diseases and
on managing related risk factors, notably diabetes.

The third area will be on evaluating possible collaborations to improve the
availability of accurate, reliable, and meaningful epidemiological studies
and registries. Both Sanofi and Ministry of Health agree that these are
critical to permit policy makers to create and shape effective and socially
impactful policies in the health sector. Therefore, Sanofi will explore the
possibilities and feasibility of engaging the Iranian scientific society to
work in these areas, and obtain and make available to the Ministry of Health
Sanofi's extensive knowledge in epidemiological studies and registries on
both national and international scales to help policy makers to address the
chronic and non-communicable diseases areas such as diabetes, cardiovascular
diseases, multiple sclerosis and rare diseases.

All evaluations will be done in accordance with applicable laws, including
trade restriction rules.

About Sanofi in Iran

Sanofi established a legal presence in the Islamic Republic of Iran in 2006
through a representative office. Also, Sanofi has been developing its
presence in the Islamic Republic of Iran since 2009 through establishing of
manufacturing collaborations for some of its core pharmaceutical products
with key local Iranian partners and thus engaged in significant technology
and know-how transfer. As a result, 55 % of the sales in Iran are with
locally manufactured products.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi has core strengths
in the field of healthcare including diabetes solutions, human vaccines,
innovative drugs, consumer healthcare, emerging markets, animal health and
Genzyme. Sanofi is listed in Paris (EURONEXT:SAN) and in New York (NYSE:SNY).

Forward-Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions,
statements regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services, product
development and potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words "expects",
"anticipates", "believes", "intends", "estimates", "plans" and similar
expressions. Although Sanofi's management believes that the expectations
reflected in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or implied or
projected by, the forward-looking information and statements. These risks and
uncertainties include among other things, the uncertainties inherent in
research and development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or biological
application that may be filed for any such product candidates as well as
their decisions regarding labelling and other matters that could affect the
availability or commercial potential of such product candidates, the absence
of guarantee that the product candidates if approved will be commercially
successful, the future approval and commercial success of therapeutic
alternatives, the Group's ability to benefit from external growth
opportunities, trends in exchange rates and prevailing interest rates, the
impact of cost containment initiatives and subsequent changes thereto, the
average number of shares outstanding as well as those discussed or identified
in the public filings with the SEC and the AMF made by Sanofi, including
those listed under "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the
year ended December 31, 2014. Other than as required by applicable law,
Sanofi does not undertake any obligation to update or revise any
forward-looking information or statements.


| Media Relations Investor |
| Relations |
|Laurence Bollack |
| Sébastien |
|Tel. : +33 (0)1 53 77 46 46 Martel |
| |
| Tel. : +33 (0)1 53 77 45 45 |
| |
Press release (PDF)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sanofi via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.